News

The pair of pulmonology and microbiology experts join the podcast to discuss what clinicians should look out for in indoor pollutant exposure risks, and how to manage their impact.

Dr. Jula Inrig explains the mechanism of action for the Dual Endothelin Angiotensin Receptor Antagonist (DEARA) investigational candidate Sparsentan, for rare kidney diseases.

The investigators found that depression increased the odds of systemic steroid administrations, the use of 2 or more molecular targeted drugs, and surgery in patients with ulcerative colitis.

Overall, 82 participants agreed to receive DBS testing, 28% of which reported that the aspects of the program made them feel uncomfortable.

A recent research letter highlighted the importance of diversity in the field of dermatology, citing the lack of diversity among trainees in the field.

Difluprednate treatment after AGV implantation resulted in a similar IOP and fewer glaucoma medications compared with prednisolone acetate.

New trial data presented at ACAAI 2022 suggest a potential insight into treating chronic spontaneous urticaria after a period of omalizumab treatment.

An online survey of adult patients shows a strong desire for a singular, consistent topical option.

Sleep Medicine Expert Daniel Gottlieb, MD, MPH, details a response to the USPSTF screening recommendations for obstructive sleep apnea in a primary care setting.

Similar visual and anatomical outcomes were observed through 1 year, despite fewer injections in the mandated quarterly treated group.

US Prevention Services Task Force (USPSTF) announces that after reviewing the clinical utility of obstructive sleep apnea screening tools in a primary care setting, there's insufficient evidence to determine the balance between benefit and harm.

Anti-brolucizumab ADAs may be a risk factor for intraocular inflammation and retinal occlusive vasculitis in patients treated with brolucizumab.

Cognitive Behavioral Therapy (CBT) for insomnia is the front-line treatment for sleep disturbance. However, the effectiveness of this approach for those with primary brain tumors hasn't been evaluated until now.

New data presented at ACAAI 2022 observed various trends in allergies associated with eczema and eosinophilic esophagitis, comparing observed data with that of patients in the United States.

New registry analysis shows persistent treatment with the IL-23 improved disease in patients predominately with a history of past biologic therapies.

"Having the ability to enhance the sleep quality in a way that is scientifically important, and also taking into account objective measurements opens a lot of possibilities," Gary Garcia-Molina, PhD, said in an interview.

Researchers tested the newly-designed Rosacea Area and Severity Index, or RASI, against the Investigator’s Global Assessment tool used to assess rosacea concerns for patients.

New pooled phase 3 data presented at ACAAI 2022 supports the FDA's approval of dupilumab for eosinophilic esophagitis.

Approximately 20 million individuals in the US were living with AMD in 2019, including 18.34 million with early-stage AMD and 1.49 million with late-stage AMD.

Greater glaucoma polygenic risk was associated with faster structural and functional progression in early POAG, despite individuals receiving more intensive treatment.

In this episode, our hosts are joined by Lydia Alexander, MD, president-elect of the Obesity Medicine Association, to discuss the updates in the landscape of obesity management as well as a deep dive into the recent American Gastroenterological Association guidelines for pharmacological management and the OMA's annual meeting.

An expert rheumatologist provides an overview of the MIRROR trial and the reduction in tophus observed among patients with gout included in the trial.

In a recent study, patients with plaque psoriasis or vitiligo who were receiving phototherapy were found to have higher rates of skin cancer than the general population.

New research suggests that certain interleukin-17 blockage therapies may not alleviate sleeping issues in patients with psoriasis.

Intravitreal aflibercept, bevacizumab and ranibizumab were each associated with comparable significant decreases in RGCL thickness in nAMD.

Will the complement C5 inhibitor drug receive FDA approval in 2023? Lally discusses this and more on the latest DocTalk.

A discussion with Dr. Lal regarding a recent 12-week trial evaluating the use of topical berdazimer gel for molluscum contagiosum.

The analysis additionally suggested the potential benefits of finerenone in the prevention of required ocular interventions.